黑龙江省哈尔滨市亚布力滑雪旅游度假区凭借优质的雪质、完善的设施和丰富的业态，让"冷资源"持续 释放"热效应"。 图为游客在亚布力滑雪旅游度假区滑雪。 唐守弘摄（人民图片） 苏华在滑雪场巡护。 本报记者 郭晓龙摄 苏华在救助摔伤游客。 本报记者 郭晓龙摄 "零下19℃，风力2级，雪道能见度良好。"清晨7时半，黑龙江亚布力阳光度假村滑雪场的缆车尚未启 动，55岁的滑雪巡救队队长苏华就已经换好速干衣和雪服，手里的救援包沉甸甸的——装着纱布、绷 带、水果糖和对讲机，这是他工作的"标配"。 2024年，"滑雪巡救员"正式列入国家新职业目录。这个小众岗位，如今成为冰雪经济中不可或缺的专业 力量。从业二十载、累计参与救援1000余次的苏华，正是这场职业蜕变的亲历者与见证者。 筑牢雪场安全防线 "这个雪季已经忙了两个多月，每天都是和晨光一起'打卡'雪道。"苏华边说边踏上缆车，前往山顶的巡 护起点。他的巡护范围覆盖11条雪道，总长度超10公里，每天要面对数千名游客的安全保障需求。黑龙 江的冬季，气温常跌至-20℃以下，大风天气更是家常便饭，这给巡救工作带来了不小的挑战。 "风大的时候，安全网会被吹倒，树枝也可能折断落到雪道上， ...

二〇二五年二月，楼天佑（中）作品被法国奥斯莫提克博物馆收录。图为楼天佑与博物馆工作人员合 影。 受访者供图 "气味是无形的语言，却能传递记忆与情感。"青年调香师楼天佑如是说。十年来，他深耕调香这一相对 小众的职业领域，在分子解构与灵感迸发的交织中，走出了一条属于中国调香师的独特道路。 嗅觉启蒙 楼天佑对气味的敏感，早已刻进童年记忆。家乡浙江花木繁盛、蔬果丰饶，清冽醇厚的蜡梅香、厨房的 食物香气以及母亲的香水气味都滋养着他的嗅觉。 家庭环境的熏陶，更让这份嗅觉感知扎根生长。家中有亲戚爱好合香，擅长制作线香、香丸等传统香 品。在耳濡目染间，楼天佑初步触碰到香气调制的奥秘，在心中埋下了探索的种子。 15岁那年，楼天佑偶然结识了一名在美国工作的法国调香师并成为其学徒。最初，他通过邮件与师父交 流，直到赴美读大学后，才得以在空闲时间近距离随师父学习调香技艺。"那时候单纯痴迷于调香，觉 得特别有意思。"他说。 在美国宾夕法尼亚州立大学，楼天佑主修材料科学与工程专业。在他眼中，这门看似与调香无关的学 科，实则暗藏共通之处。"材料学研究物质组分对最终产物特性的影响，这和调香异曲同工。调香时， 哪怕是少量分子的增减，都可能让香 ...

国台办近日宣布将台湾内务部门负责人刘世芳、教育部门负责人郑英耀列为"台独"顽固分子，依法实施 惩戒，将"绿色司法打手"陈舒怡列为"台独"打手帮凶，依法终身追责。截至目前，已公布的"台独"顽固 分子达14人、"台独"打手帮凶有12人。此次公开惩治3名"台独"分子，对企图分裂国家的"台独"势力给 出又一记当头棒喝，对其形成有力震慑。 "台独"分子是分裂国家、破坏两岸关系的违法犯罪分子，也是谋"独"引战、损害同胞利益福祉的民族败 类。近年来，民进党当局"闻统色变""逢中必反"，恶行擢发难数，如今更是花样翻新、变本加厉。刘世 芳此前被列为"台独"打手帮凶，因煽动分裂国家和分裂国家的言行更加猖獗、犯罪行为更加严重，此番 被"罪加一等"，列入"台独"顽固分子清单。 赖清德上台后将大陆界定为"境外敌对势力"，违逆民意抛出所谓"17项策略"，大搞"绿色独裁"。刘世芳 趋炎附势、卖力落实，赤裸裸宣扬"台独"分裂谬论，大肆打压支持、参与两岸交流合作的台湾人士，迫 害在台大陆配偶，极力阻碍两岸人员正常往来，封堵两岸民众交流沟通渠道，可谓劣迹斑斑。 当前台海形势复杂严峻，根源在于民进党当局顽固坚持"台独"分裂立场，拒不承认体现一个中 ...

江苏省苏州工业园区加快建设开放创新的世界一流高科技园区，发展纳米新材料、生物医药及高端医疗 器械产业。图为苏州一家医疗科技公司内，工程师在记录研发数据。 陈雨禾摄（新华社发） 服务业扩大开放综合试点开展以来，中国服务业开放持续提速加力，惠及范围越来越广。近日，商务部 印发《大连等9城市服务业扩大开放综合试点任务》（以下简称《试点任务》），服务业扩大开放综合 试点扩围有了最新"路线图"。对此，商务部外资司有关负责人回答了记者提问。 试点示范取得显著成效 国家服务业扩大开放综合试点示范是中国推出的重要开放举措。 2015年起，中国先后在北京等11个省市开展试点。2025年4月，国务院印发《关于〈加快推进服务业扩 大开放综合试点工作方案〉的批复》，明确将大连、宁波、厦门、青岛、深圳、合肥、福州、西安、苏 州等9个城市纳入试点范围。 试点示范已经取得显著成效。数据显示，2024年北京等11个省市服务业吸收外资412.6亿美元，约占全 国服务业吸收外资的50.2%，覆盖金融、教育、医疗健康、数字服务等多个关键领域。 新一批试点城市如何推动服务业扩大开放？2025年底召开的中央经济工作会议指出，有序扩大服务领域 自主开放 ...

当地时间11日，丹麦、瑞典、德国等欧洲多国政要发声，再次就美国方面日前发出的对丹麦自治领地格 陵兰岛的"威胁性言论"表示强烈批评。 德国副总理兼财政部长拉尔斯·克林拜尔11日说，美国应尊重国际法和领土主权，格陵兰岛的未来不由 美国决定。克林拜尔当天启程前往美国华盛顿参加七国集团财长会议时说，决定格陵兰岛的未来"完全 是丹麦和格陵兰岛的事情"。他强调，尊重主权和领土完整等国际法原则适用于所有国家，"包括美 国"。克林拜尔还说，作为北约盟友，各方应"共同加强北极地区安全，而不是相互对立"。 格陵兰岛是丹麦自治领地，有高度自治权，国防和外交事务由丹麦政府掌管。美国总统特朗普2025年上 任以来多次扬言要得到格陵兰岛，并声称不排除动用武力的可能性。特朗普4日接受美国《大西洋》月 刊电话采访时称，委内瑞拉可能不会是美国干预的最后一个国家，并称美国"绝对需要格陵兰岛"。对 此，丹麦等欧洲国家强烈反对。丹麦首相弗雷泽里克森警告说，如果美国对北约盟国采取军事行动， 则"一切都将终结"。 （文章来源：央视新闻） 丹麦议会国防委员会主席拉斯穆斯·亚勒乌11日接受采访时表示，如果因格陵兰岛发生军事冲突，那将 是"历史上最愚蠢的战争 ...

公告称，此溢利主要由于(i)资源投资分部的溢利贡献，而于24╱25年财政年度上半年的分部亏损约为 1.836亿港元及(ii)一间联营公司的预期减值亏损拨回所致，而24╱25年财政年度上半年于联营公司的权 益的减值亏损净额约为1.051亿港元。 格隆汇1月12日丨亚太资源(01104.HK)发布公告，相比截至2024年12月31日止六个月("24╱25年财政年 度上半年")股东应占亏损约3.099亿港元，集团预期截至2025年12月31日止六个月("25╱26年财政年度上 半年")录得股东应占溢利的估计范围约为14亿港元至19亿港元。 ...

Core Insights - Esperion reported preliminary full-year 2025 U.S. net product sales of $156 to $160 million, reflecting a 35% to 38% increase compared to 2024 [1] - The company anticipates total preliminary revenue of $400 to $408 million for 2025, marking a 20% to 23% increase from the previous year, and a 55% to 59% increase when excluding one-time milestones [1] - Esperion introduced its Vision 2040 growth strategy, aiming to evolve into a multi-product, sustainable, innovation-driven global pharmaceutical company [2][4] Financial Performance - Cash and cash equivalents at year-end 2025 are approximately $168 million [1] - Q4 retail prescription equivalents grew by 34% year-over-year and 11.3% quarter-over-quarter [1] - The company expects operating expenses for full-year 2026 to be between $210 million and $245 million [1][14] Vision 2040 Strategy - Vision 2040 aims to establish Esperion as a leader in cardiometabolic indications and expand its pipeline into rare hepatic and renal diseases [4][6] - The strategy includes plans to develop at least five marketed products and a robust pipeline addressing unmet medical needs [4] - Esperion intends to leverage its commercial infrastructure for partnerships, acquisitions, and co-promotion opportunities [5] U.S. Commercial Strategy - NEXLETOL® and NEXLIZET® are FDA-approved for cardiovascular disease prevention, targeting over 70 million patients in the U.S. [7] - The company is focusing on the statin intolerant or resistant market, which constitutes approximately 30% of the overall market [8] - Esperion has strengthened access and reimbursement support for its products, achieving over 90% coverage among commercial lives and Medicare beneficiaries [11] Global Expansion - Esperion has made significant progress in expanding its bempedoic acid products internationally, treating over 600,000 patients across 30 EU countries [12] - The company secured regulatory approval for NILEMDO in France and is advancing oral triple combination lipid-lowering tablets [12] R&D Pipeline - Esperion is advancing its ACLY-focused pipeline, targeting multiple life-threatening diseases with next-generation inhibitors [13][17] - The company nominated ESP-2001 for preclinical development, which addresses primary sclerosing cholangitis and represents a potential market opportunity exceeding $1 billion annually [17] Financial Flexibility - Esperion completed a $75 million capital raise in 2025 to support commercial expansion and pipeline development [14]

Core Insights - Zymeworks Inc. has outlined its strategic priorities and key milestones for 2026, focusing on maximizing value creation for patients, partners, and shareholders following significant progress in 2025 [1][2] 2025 Accomplishments - The company achieved positive Phase 3 results for Ziihera in treating HER2-positive gastroesophageal adenocarcinoma, with potential milestone payments of up to $440 million related to regulatory approvals in multiple regions [3][4] - Zymeworks reported cash resources of approximately $270.6 million as of December 31, 2025, which, along with anticipated milestone payments, is expected to provide a cash runway beyond 2028 [3][16][17] - A share repurchase plan of $125 million was announced to reduce share count and enhance shareholder value [3][12] Strategic Focus for 2026 - The company aims to integrate royalty growth, strategic acquisitions, and internal R&D innovation to drive long-term value creation [5][6] - Zymeworks plans to pursue partnerships and acquisitions based on strategic fit rather than immediate cash needs, emphasizing a disciplined approach to capital allocation [5][6] Clinical Development and Pipeline - Ongoing clinical studies for ZW191 and ZW251 are set to continue in 2026, with plans for future IND filings for multispecific programs [9][10] - The company anticipates presenting additional data from its clinical trials at major medical meetings in 2026 [13] Leadership and Governance - Zymeworks strengthened its leadership team and board of directors by adding experienced biotech executives [2][8] Financial Guidance - The company has outlined a disciplined framework for adjusted gross operating expenditures of approximately $300 million over three years, with a focus on cost discipline and capital allocation [15]

Core Insights - Esperion reported preliminary full-year 2025 U.S. net product sales of $156 to $160 million, reflecting a 35% to 38% increase compared to 2024 [1] - Total preliminary revenue is expected to be between $400 million and $408 million, marking a 20% to 23% increase from 2024, and a 55% to 59% increase when excluding one-time milestones [1] - The company introduced its Vision 2040 growth strategy, aiming to evolve into a multi-product, sustainable, innovation-driven global pharmaceutical company [2][4] Financial Performance - Esperion's cash and cash equivalents at year-end 2025 are approximately $168 million [1] - The company expects operating expenses for full-year 2026 to be between $210 million and $245 million [1][14] - A capital raise of $75 million was completed in 2025 to enhance financial flexibility [14] Product and Market Strategy - The U.S. commercial strategy focuses on NEXLETOL and NEXLIZET, which are approved for cardiovascular disease prevention [7] - Esperion's commercialization efforts are targeting the statin intolerant or resistant market, which constitutes about 30% of the overall market [8] - The company plans to introduce two triple combination products that could lower LDL-C by over 60%, potentially rivaling existing therapies [11] Global Expansion - Esperion has expanded its bempedoic acid products to over 30 countries in the EU, treating more than 600,000 patients [12] - The company has secured regulatory approvals in key markets, including France and Japan, enhancing its global footprint [12][16] R&D Pipeline - Esperion is advancing its ACLY-focused pipeline, targeting multiple life-threatening diseases with next-generation inhibitors [13] - The company nominated ESP-2001 for preclinical development, which addresses primary sclerosing cholangitis and represents a potential market opportunity exceeding $1 billion annually [17] Strategic Initiatives - Esperion has reached settlement agreements with four key ANDA filers to restrict generic entry until April 2040, strengthening its market position [11] - The company has enhanced access and reimbursement support for its products, achieving over 90% coverage among commercial lives and Medicare beneficiaries [11]

Core Insights - Teva Pharmaceutical Industries Ltd. is set to present its ongoing transformation and growth trajectory through 2030 at the 44th Annual J.P. Morgan Healthcare Conference [1] - The presentation will highlight milestones achieved in 2025, transformative initiatives, and a forward-looking outlook for 2026 and beyond [1] Financial Performance Outlook - Expected revenues for 2025 are projected to be between $16.8 billion and $17.0 billion, with a lower point of the range contributing an additional $500 million from duvakitug milestones [3] - Operating margin is anticipated to be around 26.2% to 27.1%, with a mid to high point of the range contributing approximately 80%-85% [3] - Adjusted EBITDA is expected to be between $4.8 billion and $5.0 billion, with a midpoint of the range contributing around $400 million to $430 million [3] - The diluted EPS is projected to be between $2.55 and $2.65, with the higher point of the range being emphasized [3] - Free cash flow is expected to be between $1.6 billion and $1.9 billion, with a higher point of the range contributing approximately $500 million [3] - Net leverage is projected to be around 2.5x to 2.9x, with a midpoint of the range at approximately 2.5x [3] Future Growth Strategy - Teva is accelerating its "Pivot to Growth" strategy, focusing on becoming a leading innovative biopharmaceutical company, supported by its generics business [6] - Key innovative brands such as AUSTEDO, AJOVY, and UZEDY are driving growth and reshaping the financial outlook [6] - The clinical pipeline includes assets like olanzapine LAI, DARI, duvakitug, emrusolmin, and anti-IL-15, which are expected to support long-term growth [6] - For 2026, revenues are expected to be flat to slightly down compared to 2025, with low-single digit growth anticipated for 2027 and mid-single digit CAGR by 2030 [5] - Operating profit is expected to grow by 30% in 2027, with free cash flow projected to exceed $2.7 billion [5]